key: cord-0953310-kitqls5h
authors: Shi, Yuejun; Shi, Jiale; Sun, Limeng; Tan, Yubei; Wang, Gang; Guo, Fenglin; Hu, Guangli; Fu, Yanan; Fu, Zhen F.; Xiao, Shaobo; Peng, Guiqing
title: Insight into Vaccine Development for Alphacoronaviruses Based on Structural and Immunological Analyses of Spike Proteins
date: 2021-03-10
journal: J Virol
DOI: 10.1128/jvi.02284-20
sha: e0edb15561847839475cb3b825ef49172e4f2fb7
doc_id: 953310
cord_uid: kitqls5h

Coronaviruses that infect humans belong to the Alphacoronavirus (including HCoV-229E) and Betacoronavirus (including SARS-CoV and SARS-CoV-2) genera. In particular, SARS-CoV-2 is currently a major threat to public health worldwide. The spike (S) homotrimers bind to their receptors via the receptor-binding domain (RBD), which is a major target to block viral entry. In this study, we selected Alphacoronavirus (HCoV-229E) and Betacoronavirus (SARS-CoV and SARS-CoV-2) as models. Their RBDs exist two different conformational states (“lying” or “standing”) in the prefusion S-trimer structure. Then, the differences in the immune responses to RBDs from these coronaviruses were analyzed structurally and immunologically. Our results showed that more RBD-specific antibodies (antibody titers: 1.28 × 10(5) and 2.75 × 10(5), respectively) were induced by the S-trimer with the RBD in the standing state (SARS-CoV and SARS-CoV-2) than the S-trimer with the RBD in the lying state (HCoV-229E; antibody titers: <500), and more S-trimer-specific antibodies were induced by the RBD in the SARS-CoV and SARS-CoV-2 (antibody titers: 6.72 × 10(5) and 5 × 10(5), respectively) than HCoV-229E (antibody titers: 1.125 × 10(3)). Besides, we found that the ability of the HCoV-229E RBD to induce neutralizing antibodies was lower than S-trimer, and the intact and stable S1 subunit was essential for producing efficient neutralizing antibodies against HCoV-229E. Importantly, our results reveal different vaccine strategies for coronaviruses, and S-trimer is better than RBD as a target for vaccine development in Alphacoronavirus. Our findings will provide important implications for future development of coronavirus vaccines. IMPORTANCE Outbreaks of coronaviruses, especially SARS-CoV-2, pose a serious threat to global public health. Development of vaccines to prevent the coronaviruses that can infect humans has always been a top priority. Coronavirus spike (S) protein is considered a major target for vaccine development. Currently, structural studies have shown that Alphacoronavirus (HCoV-229E) and Betacoronavirus (SARS-CoV and SARS-CoV-2) RBDs are in “lying” and “standing” states in the prefusion S-trimer structure. Here, we evaluated the ability of S-trimer and RBD to induce neutralizing antibodies among these coronaviruses. Our results showed that the S-trimer and RBD are both candidates for subunit vaccines in Betacoronavirus (SARS-CoV and SARS-CoV-2) with an RBD standing state. However, for Alphacoronavirus (HCoV-229E) with an RBD lying state, the S-trimer may be more suitable for subunit vaccines than the RBD. Our results will provide novel ideas for the development of vaccines targeting S protein in the future.

facilitate the development of coronavirus vaccines. In this study, we selected SARS-CoV, SARS-CoV-2, and HCoV-229E as models, which exist in two RBD conformational states, and evaluated the ability of S-trimer and RBD to induce neutralizing antibodies. Moreover, we provide possible vaccine strategies for alpha-and beta-CoVs, which may facilitate the design and development of coronavirus vaccines in the future.

Structural and immunological analyses of alpha-and beta-coronavirus spike proteins. To date, multiple S-trimer structures of coronaviruses have been resolved (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Through structural comparison, we found that although the amino acid sequences are quite different, the compositions and structures of different functional domains of coronaviruses are consistent (Fig. 1A) . All the alpha-CoVs bind to protein receptors with CTDs (as receptor-binding domains [RBDs] ), and the RBDs are in a lying state (12, 14, 16, 22, 26, 27) (Fig. 1B) . However, beta-CoVs (SARS-CoV, SARS-CoV-2, and MERS-CoV) bind receptors with CTDs (as RBDs), and the RBDs are in a standing state (13, 20, 21) (Fig. 1B) . The RBD directly binds to receptors, which is an important target for the induction of neutralizing antibody (NAb).

Then, we performed B-cell epitope predictions for the S-trimers and RBDs of alpha-CoV (HCoV-229E) and beta-CoVs (SARS-CoV and SARS-CoV-2). The predicted positive Vaccine Development for Coronavirus Spike Protein Journal of Virology residues (the corresponding spatial epitope and linear epitope) are displayed on the structural surface ( Fig. 2A , C, and E), and the distribution of positive residues on the RBD is summarized in Table 1 . A total of 51 and 26 amino acid residues located on the RBD were predicted to be conformational epitopes for SARS-CoV and SARS-CoV-2, respectively. Of these, 47 and 25 residues were located in the RBM subdomains of SARS-CoV and SARS-CoV-2, respectively. The linear B-cell epitope prediction results were similar in SARS-CoV and SARS-CoV-2. However, in HCoV-229E, only 3 residues located in the RBM subdomain were predicted to be conformational epitopes, and 9 residues were predicted to be linear epitopes. The same results also appeared in the HCoV-229E S-trimer; fewer positive residues were located in the RBD than in the SARS-CoV or SARS-CoV-2 RBM subdomain ( Fig. 2A , C and E). Meanwhile, we analyzed the binding area of the RBD and receptors from SARS-CoV, SARS-CoV-2, and HCoV-229E ( Fig. 2B , D, and F). Among them, the interaction areas of SARS-CoV and SARS-CoV-2 were similar (approximately 829.7 Å 2 and 843.5 Å 2 , respectively) and were larger than that of HCoV-229E (approximately 497 Å 2 ). Furthermore, surface area analysis also yielded consistent results (Fig. 2B , D, and F). Compared with HCoV-229E, the larger surface areas and binding areas of the SARS-CoV and SARS-CoV-2 RBDs to the receptor may induce more NAbs. The cryo-electron microscopy (cryo-EM) structures of S-trimers in the prefusion conformation have shown that the SARS-CoV and SARS-CoV-2 RBDs are in a standing state (13, 20, 21) ; however, HCoV-229E RBDs are in a lying state (16) (Fig. 1B) . Hence, compared with HCoV-229E, this may make it difficult for SARS-CoV and SARS-CoV-2 to evade neutralizing antibodies that target RBD recognition. Distinct immunogenicity of the RBDs in Alpha-CoV (HCoV-229E) and Beta-CoV (SARS-CoV and SARS-CoV-2). To evaluate the immunogenicity of the S-trimers and RBDs between Alpha-CoV (HCoV-229E) and Beta-CoV (SARS-CoV and SARS-CoV-2), the recombinant S proteins were expressed and purified (Fig. 3A , E, I, and K). Because the prefusion-stabilized S proteins could influence RBD standing or lying conformational states, two proline substitutions in the loop between the heptad repeat (HR1) and the central helix (CH) have not been introduced (31, 37) . For in vitro binding measurements (Fig. 3B , F, J, and L; Table 2 ), the equilibrium dissociation constants (K D s) of HCoV-229E spike proteins (S-trimer and RBD) and hAPN are 3.29 6 0.0129 nM and 36.0 6 0.037 nM, respectively. Besides, the K D values of SARS-CoV spike proteins (S-trimer and RBD) and hACE2 are 246 6 21.1 nM and 38.8 6 2.05 nM, respectively. Compared with previous research (26) , our results showed that all the spike proteins function well in vitro. Then, the S-trimer (10 mg) and RBD (10 mg) were used as antigens to immunize mice. The antibody response was measured via enzyme-linked immunosorbent assay (ELISA) using collected sera. The data showed that the S-trimer and RBD of SARS-CoV and To confirm this finding, a higher immunization dose of the HCoV-229E RBD (50 mg) was used in the same manner. Nevertheless, no significant increase in the RBD-specific antibody titer (antibody titers: 1.792 Â 10 6 and 3.072 Â 10 6 ) ( Fig. 3G ) or antibody titer for the HCoV-229E S-trimer (antibody titers: 2.5 Â 10 2 and 2.5 Â 10 2 ) ( Fig. 3H ) was noted. Overall, our immune epitope analysis and biochemical tests consistently showed that the S-trimer with a standing RBD state is more conducive to inducing RBD-specific antibodies in SARS-CoV and SARS-CoV-2. However, the S-trimer with a lying RBD state induces fewer RBD-specific antibodies in HCoV-229E.

HCoV-229E RBD induced fewer specific neutralizing antibodies than those of SARS-CoV and SARS-CoV-2. Next, we tested the neutralizing ability of the sera using a vesicular stomatitis virus (VSV)-based pseudovirus (100 50% tissue culture infective doses [TCID 50 ]/well). Both the S-trimer and RBD sera from SARS-CoV-and SARS-CoV-2immunized mice had a good neutralizing ability ( Fig. 4I and J) . For HCoV-229E, the Strimer sera had a neutralizing ability comparable to that of SARS-CoV or SARS-CoV-2, but the RBD sera had no detectable neutralizing ability (Fig. 4K) . Based on the results, we speculate that the antibodies induced by HCoV-229E RBD contain only a small part of neutralizing antibodies, which may be the reason for the weak ability of RBD sera to neutralize viruses. In HCoV-229E, the distribution of the potential B-cell epitopes in the RBD was lower than that of SARS-CoV or SARS-CoV-2 ( Fig. 2A , C, and E; Table 1 ), which may have caused fewer NAbs to be induced by the RBD. Therefore, we believe that this finding illustrates the inherent difference between the RBDs of alphaand beta-CoV. Besides, our results indicate that HCoV-229E S-trimer induces the production of very few antibodies targeting the RBD (antibody titer: ,500) (Fig. 4F ), but the S-trimer still produces strong neutralizing antibody levels; the mechanism needs further clarification.

The intact and stable S1 subunit in HCoV-229E S-trimer is a prerequisite for the production of effective NAbs. Our experimental results showed that the HCoV-229E S-trimer can induce high NAb levels, while the RBD alone is less immunogenic. Then, we explored which functional domains of the S-trimer are involved in the generation of NAbs. To clarify this issue, we immunized mice with the HCoV-229E S-trimer (10 mg), S1 (10 mg [ Fig. 3C and D]), NTD (10 mg [Fig. 5A ]), RBD (10 mg), and NTD1RBD (5 mg 1 5 mg). Besides, the HCoV-229E strain VR740 was used for the neutralizing assay. Our results indicated that the S-trimer sera had the best neutralizing ability, followed by the S1 and NTD1RBD sera, while the NTD and RBD sera alone had no detectable neutralizing effects (Fig. 5B) . Hence, our results indicate that the S1 region in the S-trimer should be the key region for NAb induction. To verify the importance of the complete S1 structure for NAb induction, we designed S-trimer mutants, namely, an NTD-deficient S-trimer (S-trimer/DNTD), the S1 subunit integrity of which was destroyed (Fig.  5C ). Compared with HCoV-229E S-trimer (K D value is 3.29 6 0.0129 nM), in vitro binding measurements showed that S-trimer/DNTD has a similar binding affinity with hAPN (K D value is 2.12 6 0.15 nM) and functions well ( Fig. 3B and Fig. 5D and E) . However, the incomplete S1 conformation significantly reduces the level of NAbs induced by the Strimer (Fig. 5F ). Taken together, these results showed that the intact and stable S1 subunit in HCoV-229E S-trimer is a prerequisite for the production of effective NAbs. Furthermore, our results showed that RBD functioned well in vitro (Fig. 3F) , which indicates that the characteristics of RBD itself may lead to the generation of fewer neutralizing antibodies than S-trimer in HCoV-229E (Fig. 4K) . Hence, we screened monoclonal antibodies using HCoV-229E S-trimer, and the results showed few antibodies targeting S1-RBD (Fig. 6A) . To further determine the ability of RBD to induce antibodies itself, we screened monoclonal antibodies targeting the S1 region and found that the Cross-reactivity of the SARS-CoV-2 S-trimer and RBD-specific sera is measured using ELISA. Mouse sera for SARS-CoV-2 S-trimer (magenta) and SARS-CoV-2 RBD (cyan) were 10-fold diluted and reacted with SARS-CoV-2 S-trimer (C) and RBD (D). (E and F) Cross-reactivity of the HCoV-229E S-trimer and RBD-specific sera is measured using ELISA. Mouse sera for HCoV-229E S-trimer (orange) and HCoV-229E RBD (green) were 2-fold diluted and reacted with HCoV-229E S-trimer (E) and RBD (F). (G and H) The antibody titers of sera from mice immunized with the HCoV-229E RBD (10 mg, brown; 50 mg, purple). Mouse sera were reacted with the HCoV-229E RBD (G) or S-trimer (H). Mouse sera were serially diluted from a 500-fold dilution. All the data are presented as the mean OD 450 6 SD (n = 3), and the IgG antibody titers of each serum were calculated as the maximum endpoint dilution that remained positive. (I, J, and K) The neutralization assay of mouse sera from the S-trimer and RBD against SARS-CoV, SARS-CoV-2, and HCoV-229E pseudoviruses. The limit of detection for the assay depends on the initial dilution and is represented by dotted lines; a reciprocal IC 90 titer of 40 was assigned. The data are presented as the mean reciprocal IC 90 titer 6 SD (n = 3). All differences between means with P , 0.05 are indicated. ns, not significant.

Journal of Virology proportion of antibodies targeting RBD was approximately 20% (Fig. 6B ). Since the S1 protein was expressed in a monomeric form, RBD is not restricted by the conformation of the surrounding domains and should be in a standing state. Therefore, our results indicate that HCoV-229E RBD may induce weaker levels of neutralizing antibodies, which may be related to its own characteristics. Furthermore, the RBD in the HCoV-229E S-trimer is in the lying state. Its own characteristics and conformational states may prompt the HCoV-229E to escape the host's immune surveillance, thereby allowing itself to circulate in the population for a long time. Potential vaccine strategies for Alphacoronavirus (HCoV-229E) and Betacoronavirus (SARS-CoV and SARS-CoV-2). We compared the structures of S-trimers and RBDs among alphacoronaviruses (Fig. 1B and Fig. 7A ). We also predicted the potential B-cell epitopes for their RBDs (Fig. 7A; Table 1 ). In Alpha-CoV, the S-trimer had a closed S1 subunit with three lying RBDs (Fig. 1B) . Moreover, the RBDs consist of a standard b-sandwich fold core and three short discontinuous loops in the same spatial region (12, 14, 16, 22, 26, 27, 38) (Fig. 7A) . Meanwhile, we performed a structural conservative analysis and the results showed that the RBD structures of HCoV-NL63, PEDV, and FIPV were similar to HCoV-229E, with root mean square deviation (RMSD) values of 1.7, 1.8, and 2.4, respectively (Fig. 7B) . Besides, the distribution of potential B-cell epitopes in the RBDs of alpha-CoVs was also similar to that of HCoV-229E ( Fig. 7A and C; Table 1 ). Based on the above data, inherent differences exist in the RBDs between alpha-and (C) Sequence alignment of alphacoronavirus S1-RBDs. The RBM or putative RBM region is shown in cyan. The predicted amino acid residues for linear (purple) and conformational (red) B-cell epitopes are also shown.

Journal of Virology beta-CoVs ( Fig. 2 and Fig. 7A and B) . However, the alpha-and beta-CoVs show high similarity in their RBDs and similar potential immune characteristics within their respective genera (Fig. 2, 4 , and 7A and B). Accordingly, we speculate that in alpha-CoVs such as HCoV-229E, subunit vaccines should prioritize the S-trimer rather than the RBD; in beta-CoVs such as SARS-CoV and SARS-CoV-2, the S-trimer and RBD are both good candidates for subunit vaccines (Fig. 8) .

In summary, we systematically analyzed the immunogenicity of the S-trimers and RBDs of Alpha-CoV (HCoV-229E) and Beta-CoV (SARS-CoV and SARS-CoV-2). Our results showed the inherent differences between the RBDs of alpha-and beta-CoVs and revealed potential identical immune characteristics in alpha-and beta-CoVs. Based on these findings, we provide potential vaccine strategies for alpha-and beta-CoVs. For alpha-CoVs, the S-trimer may be more suitable for subunit vaccines than the RBD. For beta-CoVs, SARS-CoV and SARS-CoV-2, the S-trimer and RBD are both candidates for subunit vaccines. Considering the potential influence of conformational states on immunogenicity, we will further evaluate the immunogenicity difference among the different aggregation states of S-trimer and RBD in the future. Although our inference requires more experimental data for further confirmation, our results will provide novel ideas for the development of coronavirus vaccines in the future.

Plasmid construction. According to previous research, insect codon-optimized sequences encoding the HCoV-229E S glycoprotein ectodomain (GenBank accession number NP_073551.1, residues 1 to 1116; NTD-deficient S-trimer: S-trimer/DNTD) and SARS-CoV S glycoprotein ectodomain with an R667A mutation (GenBank accession number NP_828851.1, residues 1 to 1195) were cloned into the baculovirus transfer vector pFastbac1 (Invitrogen) with a gene fragment encoding the GCN4 trimerization motif (LIKRMKQIEDKIEEIESKQKKIENEIARIKKIK) and an eight-residue Strep tag (WSHPQFEK) (21, 23). The human aminopeptidase N (hAPN) (GenBank accession number JX869059, residues 66 to 967) (39) and human FIG 8 Potential vaccine strategies for alpha-and beta-CoVs. The model showed that the RBDs of the alpha-CoV S-trimers are in a lying state. In this state, the S protein cannot bind to the receptor, which is conducive to escaping the immune response targeting the RBD, and the HCoV-229E RBDs also induce fewer NAbs than beta-CoVs (SARS-CoV and SARS-CoV-2); thus, their S-trimers can be an effective potential subunit vaccine. In beta-CoVs (SARS-CoV and SARS-CoV-2), the RBDs of the S-trimer are in a standing state, which is conducive to binding receptors, and the RBD can induce more antibodies than HCoV-229E; thus, their S-trimers and RBDs can produce more NAbs. Hence, their S-trimers and RBDs can be an effective potential subunit vaccine.

Pseudotyped-virus neutralization assay. In this study, HCoV-229E (ATCC, VR-740) was amplified using Huh7 cells, and pseudotyped viruses were produced as previously described (41) . The HEK-293T cells were transfected with 1 mg of HCoV-229E-S-D19-pcDNA3.1 (C-terminal deletion 19 amino acids [aa]), SARS-CoV-S-D22-pcDNA3.1 (C-terminal deletion 22 aa), and SARS-CoV-2-S-D18-pcDNA3.1 (C-terminal deletion 18 aa) plasmids using Exfect2000 transfection reagent (Vazyme). Besides, VSV-G-pcDNA3.1 and pcDNA3.1 were transfected as positive and negative controls, respectively. Then, the transfected cells were infected with VSV-DG-G at a multiplicity of infection (MOI) of 1. After 24 h, VSV-DG-HCoV-229E-S, VSV-DG-SARS-CoV-S, and VSV-DG-SARS-CoV-2-S (culture supernatants) were harvested and stored at 280°C until use.

For titration of these three pseudoviruses, 10-fold dilution was performed in 96-well culture plates. The cell with added pcDNA3.1-transfected supernatant was used as a control. After 48 h, the culture supernatant was removed and washed using PBS, and 20 ml of reporter lysis 5ÂBuffer (Promega; catalog no. E4030) was added to each well. Then, the luciferase substrate (Promega; catalog no. E1500) was added, and the luminescence activity was measured using a multimode microplate reader (Tecan Spark 10M). The viral titers were calculated using the Reed-Muench method.

For pseudovirus neutralization assay, 2-fold serial dilutions of mouse sera (initially 1:40) were mixed with the pseudovirus strains (HCoV-229E, SARS-CoV, and SARS-CoV-2; 100 TCID 50 /well). After 48 h, the luminescence activity was measured. According to the formula (V 2 X)/(V 2 C) Â 100% (where X is sample reading, C is cell control reading, and V is virus control reading; n = 3), the neutralization protection rate (90% inhibitory concentration [IC 90 ]) was calculated. Besides, for virus neutralization assay, 2-fold serial dilutions of mouse sera (initially 1:8) were mixed with an equal volume of HCoV-229E (ATCC, VR-740, 100 TCID 50 /well) at 37°C. After 5 days of incubation, the cytopathic effect (CPE) was observed by an inverted optical microscope. The highest serum dilution that protected more than 90% of cells from CPE was taken as the neutralization titer (IC 90 ). Serum from mice immunized with HBS was used as a control.

B-cell epitope prediction analysis. According to previous research, B-cell epitopes were predicted and analyzed (IEDB, https://www.iedb.org/) (45) . Briefly, structure-based B-cell epitope prediction was performed by DiscoTope 2.0 with a positive cutoff greater than 23.7 (corresponding to a specificity greater than or equal to 0.75 and a sensitivity less than 0.47) using the following protein structures: the HCoV-229E S-trimer and RBD (PDB IDs: 6U7H and 6ATK, respectively), the SARS-CoV S-trimer and RBD (PDB IDs: 5X5B and 2AJF, respectively), the SARS-CoV-2 S-trimer and RBD (PDB IDs: 6VYB and 6M0J, respectively), the HCoV-NL63 (PDB ID: 3KBH), the PEDV RBD (PDB ID: 6U7K), the FIPV RBD (PDB ID: 6JX7), the porcine respiratory coronavirus (PRCoV) RBD (PDB ID: 4F5C), and the transmissible gastroenteritis virus (TGEV) RBD (PDB ID: 4F2M). For linear B-cell epitope prediction, the corresponding amino acid sequences from the above structures were used. The BepiPred 2.0 algorithm was applied with a cutoff of 0.55 (corresponding to a specificity greater than 0.81 and a sensitivity less than 0.3). All the predicted residues were labeled in corresponding structures using PyMOL (Schrödinger). Besides, the interaction area and surface area were analyzed via PDBePISA (https://www.ebi.ac.uk/msd-srv/prot_int/pistart.html). Additionally, the amino acid sequences of alpha-CoV RBDs were aligned using ClustalW2 (46) . The NCBI accession numbers of the sequences used were as follows: HCoV-229E (AAQ90002.1), HCoV-NL63 (AVL25587.1), PRCoV (AAA46905.1), TGEV (CAB91145.1), PEDV (AIU98611.1), and FIPV (ACT10887.1).

Statistical analysis. Statistical analysis was carried out using GraphPad Prism 7.0. Statistical analysis was conducted on data from three independent experimental replicates. Statistical significance was determined using an unpaired two-tailed Student t test. Data are presented as mean values 6 SD (95% confidence interval). All differences between means with P , 0.05 are indicated. * indicates P , 0.05, which was considered significant, and ** indicates P , 0.01, which was considered highly significant.

Ethics statement. All the mice used in this study were maintained in compliance with the recommendations in the Regulations for the Administration of Affairs Concerning Experimental Animals established by the Ministry of Science and Technology of China. The experiments were carried out using the protocols approved by the Scientific Ethics Committee of Huazhong Agricultural University (permit number: HZAUSW-2018-009).

Protein expression and purification. The spike protein ectodomain was expressed and purified using a previously described protocol (21, 29). Briefly, the construct was transformed into bacterial DH10Bac competent cells (Invitrogen); then, the extracted bacmid was transfected into Sf9 cells (American Type Culture Collection). The supernatant of the cell culture containing the secreted S glycoprotein was harvested at 60 h after infection and concentrated, and the buffer was changed to binding buffer (10 mM HEPES, pH 7.2, and 500 mM NaCl). The S-trimer (HCoV-229E and SARS-CoV) including Strep tag was captured using StrepTactin Sepharose high-performance resin (GE Healthcare) (21)

All injections were carried out in duplicate and gave essentially identical results. Only one of the duplicates is shown. Animal immunization. Female BALB/c mice aged 6 weeks were immunized with different proteins at 0 and 3 weeks. Proteins (10 mg) diluted in HEPES-buffered saline (HBS; 10 mM HEPES and 150 mM NaCl) were mixed 1:1 with the 2ÂSigma adjuvant system. The mice were intramuscularly inoculated with 50 ml of this solution (25 ml into each hind leg). Two weeks after the final immunization, sera were collected for subsequent assays. For SARS-CoV-2, the corresponding rabbit polyclonal antibodies (PAbs) were purchased from Sino Biological, Inc. Enzyme-linked immunosorbent assay (ELISA)

PBST) containing 1% (wt/vol) bovine serum albumin (BSA) at 37°C. After standard washes, the plates were incubated with 2-or 10-fold serially diluted sera for 1 h at 37°C. Then, horseradish peroxidase (HRP)-conjugated goat anti-mouse

Beyotime) was used as the substrate for detection. Optical density (OD) was determined at 450 nm and 630 nm using a Spark 10M microplate reader (Tecan) after stopping the reaction with 2 M H 2 SO 4 . Serum from mice immunized with HBS was used as a control. Generation of HCoV-229E S protein MAbs and epitope mapping. Six-week-old female BALB/c mice were immunized with 100 mg of purified HCoV-229E S-trimer or S1 protein

F5881) for the first immunization or Freund's incomplete adjuvant

Each mouse received three subcutaneous injections at 2-week intervals. Mice with the highest titers of antibodies against the HCoV-229E

S-trimer or S1 protein were further boosted by intraperitoneal injection of 200 mg of purified HCoV-229E

or S1 protein diluted in PBS buffer. Three days after the last injection, spleen cells were collected and fused with SP2/0 cells with PEG1450

Positive hybridomas were further subcloned and used for epitope mapping. Finally, ELISA plates were coated with different proteins (the HCoV-229E Strimer, S1, S1-NTD, and S1-RBD) at 1 mg/ml in CBS (pH 9.6) overnight at 4°C and subsequently blocked and washed. Then, the plates were reacted with the hybridoma culture supernatants at 37°C for 1 h

:5,000 diluted in PBST with 1% [wt/vol] BSA; Boster) was used for detection. Signal reading was carried out in the manner described above. Hybridoma culturing medium was used as a control

Origin and evolution of pathogenic coronaviruses

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes

Medical reviews. Coronaviruses

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

MERS: emergence of a novel human coronavirus

Coronavirus as a possible cause of severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Structure, function, and evolution of coronavirus spike proteins

Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The 3.1-angstrom cryo-electron microscopy structure of the porcine epidemic diarrhea virus spike protein in the prefusion conformation

Structural basis for human coronavirus attachment to sialic acid receptors

The human coronavirus HCoV-229E S-protein structure and receptor binding

Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections

Cryo-electron microscopy structure of porcine deltacoronavirus spike protein in the prefusion state

Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy

Pre-fusion structure of a human coronavirus spike protein

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

Receptor-binding loops in alphacoronavirus adaptation and evolution

Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge

Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice

Yeastexpressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies

The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Comparison of lentiviruses pseudotyped with S proteins from coronaviruses and cell tropisms of porcine coronaviruses

A genetically encoded probe for imaging nascent and mature HA-tagged proteins in vivo

Zfp217 mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation

Stability and sub-cellular localization of DNA polymerase b is regulated by interactions with NQO1 and XRCC1 in response to oxidative stress

A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2

Clustal W and Clustal X version 2.0

This work was supported by National Key R&D Plan of China grant 2018YFD0500100, National Natural Science Foundation of China grants 31722056 and 31702249, China Postdoctoral Science Foundation grant 2019M662674, and the Huazhong Agricultural University Scientific and Technological Self-innovation Foundation (program no. 2662017PY028).We declare no competing interests.